Apricitabine News and Research

RSS

Avexa halts HIV drug trials

Melbourne-based biotech Avexa has announced the closure of its lead HIV program for apricitabine after failing to attract a licensing partner for the Phase III drug.

12 May 2010

Avexa's ATC Phase III study concludes

Avexa Limited today announced that the apricitabine (ATC) Phase III study will be closed and the data will be subsequently unblinded and analyzed. After extensive interaction with the regulatory authorities and potential partners, the decision was made to evaluate the 24 week data with the results due in the first quarter of 2010.

3 Oct 2009

Shire licenses the north American rights for Apricitabine to Avexa

Shire plc has announced that it licensed the North America (U.S. and Canada) rights for the investigational HIV compound, SPD754 (also known as apricitabine), to the Australian biotechnology company Avexa Limited in return for an up-front payment of US$10 million, development and sales related milestones and royalties.

22 Jan 2007